🔗 Share this article

While America proceeds with unprecedented adjustments to its vaccination recommendations, an unexpected name has emerged unexpectedly: Tracy Beth Høeg, an American of Danish descent sports physician and epidemiologist who initially gained attention by casting doubt on COVID-19 shots throughout the pandemic and has zeroed in on potential deaths after Covid vaccination in her short position at the US Food and Drug Administration (FDA).

Scheduled Overhauls to Pediatric Immunization Program

Public health authorities were set to announce sweeping changes to the pediatric vaccine schedule recently, aligning the US with Denmark’s immunization schedule, it is understood – a major change that would place the US out of alignment with a large portion of the international standard with insufficient data for benefit. The announcement has been pushed back until the new year.

Instead of Vinay Prasad, Dr. Høeg is set to address the audience at the meeting. She was newly appointed interim head of the FDA’s drug evaluation center, the fifth individual to lead the center this calendar year.

A Shift at the Agency

The acting appointment may indicate a tighter collaboration between the pharmaceutical and vaccine divisions as Høeg and Dr. Prasad strengthen their influence at the agency – and it signals a renewed priority upon dismantling already-approved vaccines at the FDA.

The new acting director has repeatedly called for discontinuing certain pediatric vaccine recommendations in the US to become more similar to Denmark's approach, a nation with nationalized medicine and a number of inhabitants roughly the population of Wisconsin’s.

To date public appearances, she has continued to focus on vaccines – typically the domain of Dr. Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of medication approval.

Doubts Over Expertise

The appointee has no apparent track record in medication creation, oversight or leadership, which has been typical for past directors of the Center for Biologics Evaluation and Research. She has worked at the FDA as a senior adviser to the FDA chief and CBER since spring.

“She doesn’t seem to have the requisite experience” for running the drug-regulation department, said a neurologist and psychiatrist. “She lacks experience running a clinical trial. She is not versed in running a sizeable institution. She lacks background in drug approvals.”

Previous heads of CBER would “be deeply familiar with regulatory frameworks and the underlying principles of pharmaceutical innovation”, said Janet Woodcock. “Objectively, she lacks the sort of resume that previous people who headed the center have had.”

The drug center has an immense range of responsibilities at the FDA, the former commissioner stated.

“The public just focuses on the new drug program, but the generic drug division clears a multitude of generic drugs. There is also a biosimilars division, OTC medication office and more, and all of those have to be looked after,” Dr. Woodcock said. “The thing you overlook, that is the part that I always told people is going to come back to haunt you.”

There is also, a substantial management element to the role, which oversees in excess of 5,000 employees. “It’s a huge leadership role, if you do it right,” she said.

Official Statement and Controversial Policies

When asked about inquiries about Høeg’s fitness for the role and whether this assignment represents increased cooperation among regulatory chiefs on immunizations, a press secretary said that the “inquiries rely on inaccurate presumptions”.

“Her resume matches the duties of her role,” the official stated, noting the time Høeg spent guiding the agency head on “pharmaceutical safety and approval science, including computerized risk analysis and immunization monitoring”.

In her interim role, Høeg inherits the commissioner’s recently launched priority voucher program, a contentious expedited therapy clearance system that allegedly troubled her predecessors. “How are these therapies being selected for this fast-track system? Who is making the decisions?” Dr. Howard asked. “There’s a lot of confidentiality happening at the agency right now.”

Broadly speaking, he remarked, “the agency seems to be moving towards more relaxed regulations of all drugs, aside from immunizations.”

Public Past Work on Immunizations

Regarding immunizations, Dr. Høeg has a more documented, if troubling, past, critics have noted. She released a study using unconfirmed volunteer-provided data to estimate the incidence of myocarditis after Covid immunization. She counseled the state of Florida chief medical officer Joseph Ladapo, who reportedly have changed statistics to indicate Covid vaccines are more dangerous than they are.

Part of her “wish list” for the current administration included altering regulations for recently developed shots and discontinuing “unnecessary” immunizations, she remarked following the vote on a audio program. At the FDA, Høeg has allegedly suggested preventing adolescent males from obtaining COVID-19 vaccines.

“She is an all-around dogmatist who commences with her preconceived notions and reverse-engineers to retrofit the science in a highly misleading, untruthful fashion,” Howard stated.

Taking Control and a “Campaign of Retribution”

Høeg joined fellow dissenters, {like|